Preclinical studies in mice also demonstrated that CDK4/6 inhibitors augmented the recruitment of exogenous T cells into the tumor tissue, suggesting that CDK4/6 inhibitors may sensitize patients to T-cell-delivering therapies, such as adoptive cell transfer of T cells and chimeric antigen receptors (CAR) T cells [33]. The gene discussed is CDK4; the disease is neoplasm.